It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Telomere repeats at chromosomal ends, critical to genomic integrity, undergo age-dependent attrition. Telomere length, a polygenic trait, has been associated with risk of several disorders including cancers. In contrast to association of long telomeres with increased risk of several cancers, including melanoma, emerging reports suggest that short telomeres predict poor survival in patients with different cancers. In this study based on 1019 stage I and II cutaneous melanoma patients, we show an association between the patients with short telomeres and poor melanoma-specific survival (HR 2.05, 95% CI 1.33–3.16) compared to patients with long telomeres. Due to inverse correlation between age and telomere length (r -0.19, P < 0.0001), we stratified the patients into quantiles based on age at diagnosis and also carried out age-matched analysis. The effect of short telomeres on survival was determined by using multivariate Cox regression that included composite genetic risk score computed from genotyping of the patients for telomere-length associated polymorphisms. The effect of decreased telomere length on poor melanoma-specific survival was particularly strong in patients within the age quantile below 30 years (HR 3.82, 95% CI 1.10–13.30) and between 30–40 years (HR 2.69, 95% CI 1.03–7.03). Our study shows that in contrast to increased melanoma risk associated with increased telomere length, decreased telomere length predicts poor survival in melanoma subgroups.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany
2 Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany; Institute of Medical Biostatistics, University Medical Center of Johannes Gutenberg, University of Mainz, Mainz, Germany
3 Labortory of Molecular Biology, Instituto Valenciano de Oncologia, Valencia, Spain
4 Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain
5 Department of Pathology, Instituto Valenciano de Oncologia, Valencia, Spain
6 Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain
7 Advanced Technology Center for Aging Research, Italian National Research Center on Aging (INRCA), Ancona, Italy
8 Latvian Biomedical Research and Study Centre, Riga, Latvia
9 Department of Clinical Medicine, Gade Laboratory of Pathology, Haukeland University Hospital, Bergen, Norway; Department of Pathology, Haukeland University Hospital, Bergen, Norway
10 Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands
11 Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany; German Consortium for Translational Research, German Cancer Research Center, Heidelberg, Germany